New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health

Rhea-AI Summary

LifeVantage (Nasdaq: LFVN) announced in vitro results for its proprietary P84 formula on Nov 12, 2025 showing biologically meaningful effects on 14 gut peptides and proteins linked to regulation, repair, and restoration.

Key measured changes included GRP +1,087%, TFF3 +116%, VIP +100%, OXM +77%, and CCK +69%. The study used four gut cell types and reported that P84 exceeded typical biomarker thresholds (20–30%) across multiple targets. LifeVantage said it acquired LoveBiome assets in October 2025 and will next perform mRNA sequencing combining P84 with Protandim Nrf2 Synergizer and MindBody GLP-1 System.

Positive

• GRP expression increased by +1,087%
• TFF3 expression increased by +116%
• Multiple gut targets exceeded a 20–30% biological-effect threshold
• LifeVantage acquired LoveBiome assets in October 2025, adding P84 to portfolio

Negative

• Results are in vitro only and not evidence of clinical efficacy in humans
• No human clinical trial results or clinical endpoints were reported

Insights

TranslationalScienceAnalyst

In vitro results and a recent acquisition are noteworthy but do not prove clinical benefit; near-term investor impact is limited.

The study reports strong cellular responses to the P84 formula across 14 gut-related peptides and proteins, including a +1,087% change for GRP and several other increases above a commonly cited 20-30% biological-meaningful threshold. These data describe biological activity in controlled cell models and map to mechanisms—regulation, repair, and barrier function—relevant to gut physiology.

Because the work is explicitly in vitro, it cannot demonstrate safety, efficacy, or clinical benefit in people. Translating cell-culture biomarker shifts into real-world outcomes requires reproducible in vivo studies and human trials; therefore, the announcement should be treated as early-stage mechanistic evidence rather than proof of therapeutic or large commercial effect. The disclosed October 2025 acquisition of LoveBiome is a concrete corporate event that expands product offerings and distribution channels.

Watch for three concrete next steps over the coming 6-18 months: publication or peer review of the full data set, in vivo or human study starts (including endpoints and sample size), and results from the planned mRNA sequencing analysis combining P84 with the company’s other formulas. Those milestones will materially increase the relevance of these findings to regulatory, clinical, and commercial assessments.

New in vitro research shows P84 influences key gut peptides – including one by more than 1,000% – supporting cellular pathways tied to regulation, repair, and restoration

SALT LAKE CITY, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new in vitro study results for its proprietary P84 formula revealing strong biological activity in cellular pathways linked to gut regulation, repair, and restoration.*

In the controlled, third-party study, targeted gene expression and protein concentration were measured using four gut cell types. Fourteen gut peptides and proteins known to regulate, repair, and restore the gut including CCK, NTS, EREG, GRP, OXM, CDH1, TFF3, Zonulin, CLDN1, OCLN, MUC2, GLP-2, VIP and SST were thoroughly examined.

All 14 peptides were influenced in the desired direction, with key results including: *†††

• GRP (gastrin-releasing peptide responsible for sending alerts to fire up digestion): +1,087% increase*†††
• TFF3 (trefoil factor 3 which manages gut lining repair): +116% increase*†††
• VIP (vasoactive intestinal peptide which helps to calm overactive areas of the gut): +100% increase*†††
• OXM (oxyntomodulin which coordinates nutrient absorption): +77% increase*†††
• CCK (cholecystokinin which ensures fats and proteins are properly processed): +69% increase*†††
  

“These findings demonstrate that our proprietary P84 blend has a remarkable impact on activating key processes at the cellular level,” said Lisa Barnes, Vice President of R&D and Regulatory at LifeVantage. “P84 reinforces LifeVantage’s position at the forefront of nutrigenomic innovation by positively influencing key markers necessary to ensure a strong, healthy gut. Gut health is at the root of so many things that impact people of all ages. It’s incredibly exciting to offer products that are unlike anything else, deliver meaningful change and create a lasting impact for consumers.” *

In vitro research supports scientists in their understanding of how nutrients and bioactive compounds interact with cells in a controlled environment. Typically, biomarker changes of 20-30% are considered biologically meaningful, and in these studies, P84 exceeded those thresholds across multiple targets.

The next phase of this important research will include mRNA sequencing analysis of the P84 blend in combination with the company’s Protandim^® Nrf2 Synergizer^® and MindBody GLP-1 System™ formulas.

LifeVantage brought P84 into its activating product portfolio after acquiring the critical assets of LoveBiome, a direct sales company centered on gut and microbiome health, in October 2025. P84 helps create the right environment for beneficial bacteria to thrive, restoring calm, balance and strength to your body’s “second brain”. It’s offered along with Protandim Nrf2 Synergizer as part of the Healthy Edge Stack, which helps consumers get the proactive edge on their health through cellular activation.*

To learn more about the science behind P84 and other LifeVantage products, visit www.lifevantage.com.

About LifeVantage Corporation

LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, MindBody GLP-1 System™, and the comprehensive gut activator, P84. The robust portfolio also includes activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.*

Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com

Public Relations Contact:
CerconeBrownCompany
lifevantage@cerconebrown.com

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
†††Results based on a cell culture study on P84.  

FAQ

What did LifeVantage (LFVN) announce about P84 on November 12, 2025?

LifeVantage reported in vitro study results showing P84 influenced 14 gut peptides, including GRP +1,087% and TFF3 +116%.

Do the P84 study results for LFVN represent clinical proof in humans?

No; the announcement describes in vitro cellular findings and does not present human clinical trial results.

How will P84 be developed next according to LifeVantage (LFVN)?

LifeVantage said the next phase will include mRNA sequencing of P84 combined with Protandim Nrf2 Synergizer and MindBody GLP-1 System.

When did LifeVantage add P84 to its product portfolio (LFVN)?

LifeVantage acquired critical LoveBiome assets and added P84 in October 2025.

Which peptide showed the largest increase in the P84 study announced by LFVN?

GRP showed the largest reported increase at +1,087%.